Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
10.44
-0.36 (-3.33%)
May 1, 2026, 4:00 PM EDT - Market closed
Daxor Revenue
Revenue (ttm)
$26.69K
Revenue Growth
-77.71%
P/S Ratio
2,358.14
Revenue / Employee
$593
Employees
45
Market Cap
60.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.45M | -132.91K | -8.42% |
| Dec 31, 2010 | 1.58M | -109.57K | -6.49% |
| Dec 31, 2009 | 1.69M | -72.23K | -4.10% |
| Dec 31, 2008 | 1.76M | -108.72K | -5.81% |
| Dec 31, 2007 | 1.87M | 383.33K | 25.79% |
| Dec 31, 2006 | 1.49M | 142.91K | 10.64% |
| Dec 31, 2005 | 1.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanara MedTech | 103.12M |
| Harvard Bioscience | 86.55M |
| Pro-Dex | 74.64M |
| Precision Optics Corporation | 24.42M |
| Nephros | 18.79M |
| Nyxoah | 11.76M |
| Ekso Bionics Holdings | 11.57M |
| Milestone Scientific | 8.97M |
DXR News
- 3 days ago - Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis - GlobeNewsWire
- 23 days ago - Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center - GlobeNewsWire
- 5 weeks ago - Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 - GlobeNewsWire
- 6 weeks ago - Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - GlobeNewsWire
- 7 weeks ago - Daxor Transcript: IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 - Transcripts
- 7 weeks ago - Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress - GlobeNewsWire
- 7 weeks ago - Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewsWire
- 2 months ago - Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - GlobeNewsWire